ALX Oncology Holdings Inc
NASDAQ:ALXO
Intrinsic Value
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. [ Read More ]
There is not enough data to reliably calculate the intrinsic value of ALXO.
ALX Oncology Holdings Inc's market capitalization is 810.2m USD.
ALXO stock price is 16.22 USD.
ALXO.
ALXO. Open DCF Valuation
ALXO. Open Relative Valuation
ALXO has upside potential of 27% compared to the average analyst price target.
Open Wall St Estimates
ALXO's ROE (Return on Equity) has significantly decreased in the last 3 years from -22% to -71%, and is approaching profitability.
ALXO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from 3 566% to -408%.
ALXO's Altman Z-Score is very high and is equal to 3.17.
ALXO has negative Operating Income for the last twelve months.
ALXO has negative Net Income for the last twelve months.
ALXO's ROE (Return on Equity) for the past 12 months is negative and is equal to -71%.
ALXO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -408%.
ALXO has negative Free Cash Flow for the last twelve months.
ALXO's D/E (Debt to Equity) is very low and is equal to 0.06.
ALXO has negative three-year average ROE (Return on Equity): -36%. The company is not efficient at transforming stockholders' equity into net income.
ALXO has negative three-year average ROIC (Return on Invested Capital): -530%. The company is not efficient at using invested capital to generate operating income.
ALXO's short-term assets (189m USD) exceed its short-term liabilties (36m USD).
ALXO's long-term assets (243m USD) exceed its long-term liabilties (53m USD).
ALXO has negative Net Debt. This means that the company has more cash and short-term investments (183m USD) than debt (11m USD).
ALXO doesn't generate enough operating income (-170m USD) to safely cover interest payments on its debt (1m USD).
Fundamental Analysis
ALX Oncology Holdings Inc
Balance Sheet Decomposition
ALX Oncology Holdings Inc
| Current Assets | 188.7m |
| Cash & Short-Term Investments | 182.7m |
| Receivables | 1m |
| Other Current Assets | 4.9m |
| Non-Current Assets | 53.9m |
| Long-Term Investments | 35.4m |
| PP&E | 10.8m |
| Other Non-Current Assets | 7.6m |
| Current Liabilities | 36m |
| Accounts Payable | 8.6m |
| Accrued Liabilities | 26.1m |
| Other Current Liabilities | 1.4m |
| Non-Current Liabilities | 16.8m |
| Long-Term Debt | 11.2m |
| Other Non-Current Liabilities | 5.6m |
Earnings Waterfall
ALX Oncology Holdings Inc
|
Revenue
|
0
USD
|
|
Operating Expenses
|
-170.3m
USD
|
|
Operating Income
|
-170.3m
USD
|
|
Other Expenses
|
9.5m
USD
|
|
Net Income
|
-160.8m
USD
|
Free Cash Flow Analysis
ALX Oncology Holdings Inc
ALXO Profitability Score
Profitability Due Diligence
ALX Oncology Holdings Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
Score
ALX Oncology Holdings Inc's profitability score is 15/100. The higher the profitability score, the more profitable the company is.
ALXO Solvency Score
Solvency Due Diligence
ALX Oncology Holdings Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Score
ALX Oncology Holdings Inc's solvency score is 68/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
ALXO Price Targets Summary
ALX Oncology Holdings Inc
According to Wall Street analysts, the average 1-year price target for
ALXO
is 20.55 USD
with a low forecast of 14.14 USD and a high forecast of 26.25 USD.
Ownership
ALXO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
ALXO Price
ALX Oncology Holdings Inc
| Average Annual Return | 15.82% |
| Standard Deviation of Annual Returns | 133.52% |
| Max Drawdown | -96% |
| Market Capitalization | 810.2m USD |
| Shares Outstanding | 48 996 000 |
| Percentage of Shares Shorted | 12.7% |
Company Profile
ALX Oncology Holdings Inc
Country
Industry
Market Cap
Dividend Yield
Description
ALX Oncology Holdings, Inc. operates as a clinical stage company, which engages in the research and development of therapies for cancer patients. The company is headquartered in South San Francisco, California and currently employs 43 full-time employees. The company went IPO on 2020-07-17. The firm is focused on helping patients fight cancer by developing a pipeline of product candidates based on protein engineering and oncology led by the cluster of differentiation 47 (CD47) blocker. The company is developing a checkpoint inhibitor designed to have an affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches. Its lead product candidate, evorpacept, is a CD47 blocking biologic in development as a combination therapy with other anti-cancer agents for treatment of various oncology indications, including myelodysplastic syndromes (MDS), acute myeloid leukemia (AML), head and neck squamous cell carcinomas (HNSCC), gastric and breast cancer. Its preclinical program is focused on developing ALTA-002, which combines its signal regulatory protein alpha (SIRPa) and toll-like receptor 9 agonist antibody conjugate (TRAAC).
You don't have any saved screeners yet
